Drug Safety Evaluation
-10%
portes grátis
Drug Safety Evaluation
Gad, Shayne Cox; Sullivan, Dexter W.
John Wiley & Sons Inc
01/2023
992
Dura
Inglês
9781119755852
15 a 20 dias
2518
Descrição não disponível.
PREFACE xxix
ABOUT THE AUTHORS xxxi
1 The Drug Development Process and The Global Pharmaceutical Marketplace 1
2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market 19
3 Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation 67
4 Electronic Records, Reporting, and Submission: eCTD and Send 75
5 Screens in Safety and Hazard Assessment 83
6 Formulations, Routes, and Dosage Regimens 95
7 Mechanisms And End Points Of Drug Toxicity 131
8 Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF 143
9 Repeat-Dose Toxicity Studies 173
10 Genotoxicity 183
11 QSAR Tools For Drug Safety 223
12 Toxicogenomics 241
13 Immunotoxicology In Drug Development 247
14 Nonrodent Animal Studies 293
15 Developmental And Reproductive Toxicity Testing 331
16 Carcinogenicity Studies 363
17 Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment 395
18 Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment 403
19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation 425
20 Safety Pharmacology 457
21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products 477
22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs 507
23 Special Case Products: Imaging Agents 529
24 Special Case Products: Drugs For Treatment Of Cancer 535
25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology) 543
26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology 551
27 Occupational Toxicology In The Pharmaceutical Industry 571
28 Strategy and Phasing For Nonclinical Drug Safety EvaluationIn The Discovery and Development of Pharmaceuticals 585
29 The Application of In Vitro Techniques In Drug Safety Assessment 603
30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond 635
31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs) 683
32 Statistics In Pharmaceutical Safety Assessment 707
33 Combination Products: Drugs and Devices 767
34 Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals 777
35 Tissue, Cell, and Gene Therapy 789
36 Adverse Outcome Pathways in Drug Safety Assessment 801
Appendix A: Selected Regulatory and Toxicological Acronyms 805
Appendix B: Definition Of Terms And Lexicon of "Clinical" Observations in Nonclinical (Animal) Studies 807
Appendix C: Notable Regulatory Internet Addresses 811
Appendix D: Glossary Of Terms Used in The Clinical Evaluation of Therapeutic Agents 817
Appendix E: Common Vehicles For The Nonclinical Evaluation of Therapeutic Agents 821
Appendix F: Global Directory of Contract Toxicology Labs 919
INDEX 945
ABOUT THE AUTHORS xxxi
1 The Drug Development Process and The Global Pharmaceutical Marketplace 1
2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market 19
3 Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation 67
4 Electronic Records, Reporting, and Submission: eCTD and Send 75
5 Screens in Safety and Hazard Assessment 83
6 Formulations, Routes, and Dosage Regimens 95
7 Mechanisms And End Points Of Drug Toxicity 131
8 Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF 143
9 Repeat-Dose Toxicity Studies 173
10 Genotoxicity 183
11 QSAR Tools For Drug Safety 223
12 Toxicogenomics 241
13 Immunotoxicology In Drug Development 247
14 Nonrodent Animal Studies 293
15 Developmental And Reproductive Toxicity Testing 331
16 Carcinogenicity Studies 363
17 Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment 395
18 Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment 403
19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation 425
20 Safety Pharmacology 457
21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products 477
22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs 507
23 Special Case Products: Imaging Agents 529
24 Special Case Products: Drugs For Treatment Of Cancer 535
25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology) 543
26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology 551
27 Occupational Toxicology In The Pharmaceutical Industry 571
28 Strategy and Phasing For Nonclinical Drug Safety EvaluationIn The Discovery and Development of Pharmaceuticals 585
29 The Application of In Vitro Techniques In Drug Safety Assessment 603
30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond 635
31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs) 683
32 Statistics In Pharmaceutical Safety Assessment 707
33 Combination Products: Drugs and Devices 767
34 Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals 777
35 Tissue, Cell, and Gene Therapy 789
36 Adverse Outcome Pathways in Drug Safety Assessment 801
Appendix A: Selected Regulatory and Toxicological Acronyms 805
Appendix B: Definition Of Terms And Lexicon of "Clinical" Observations in Nonclinical (Animal) Studies 807
Appendix C: Notable Regulatory Internet Addresses 811
Appendix D: Glossary Of Terms Used in The Clinical Evaluation of Therapeutic Agents 817
Appendix E: Common Vehicles For The Nonclinical Evaluation of Therapeutic Agents 821
Appendix F: Global Directory of Contract Toxicology Labs 919
INDEX 945
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
pharmaceutical safety; drug development covid; drug development safety; drug development regulation; evaluate pharmaceutical safety; pharmaceutical testing; drug testing; pharmaceutical regulations; clinical drug development
PREFACE xxix
ABOUT THE AUTHORS xxxi
1 The Drug Development Process and The Global Pharmaceutical Marketplace 1
2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market 19
3 Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation 67
4 Electronic Records, Reporting, and Submission: eCTD and Send 75
5 Screens in Safety and Hazard Assessment 83
6 Formulations, Routes, and Dosage Regimens 95
7 Mechanisms And End Points Of Drug Toxicity 131
8 Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF 143
9 Repeat-Dose Toxicity Studies 173
10 Genotoxicity 183
11 QSAR Tools For Drug Safety 223
12 Toxicogenomics 241
13 Immunotoxicology In Drug Development 247
14 Nonrodent Animal Studies 293
15 Developmental And Reproductive Toxicity Testing 331
16 Carcinogenicity Studies 363
17 Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment 395
18 Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment 403
19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation 425
20 Safety Pharmacology 457
21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products 477
22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs 507
23 Special Case Products: Imaging Agents 529
24 Special Case Products: Drugs For Treatment Of Cancer 535
25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology) 543
26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology 551
27 Occupational Toxicology In The Pharmaceutical Industry 571
28 Strategy and Phasing For Nonclinical Drug Safety EvaluationIn The Discovery and Development of Pharmaceuticals 585
29 The Application of In Vitro Techniques In Drug Safety Assessment 603
30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond 635
31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs) 683
32 Statistics In Pharmaceutical Safety Assessment 707
33 Combination Products: Drugs and Devices 767
34 Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals 777
35 Tissue, Cell, and Gene Therapy 789
36 Adverse Outcome Pathways in Drug Safety Assessment 801
Appendix A: Selected Regulatory and Toxicological Acronyms 805
Appendix B: Definition Of Terms And Lexicon of "Clinical" Observations in Nonclinical (Animal) Studies 807
Appendix C: Notable Regulatory Internet Addresses 811
Appendix D: Glossary Of Terms Used in The Clinical Evaluation of Therapeutic Agents 817
Appendix E: Common Vehicles For The Nonclinical Evaluation of Therapeutic Agents 821
Appendix F: Global Directory of Contract Toxicology Labs 919
INDEX 945
ABOUT THE AUTHORS xxxi
1 The Drug Development Process and The Global Pharmaceutical Marketplace 1
2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market 19
3 Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation 67
4 Electronic Records, Reporting, and Submission: eCTD and Send 75
5 Screens in Safety and Hazard Assessment 83
6 Formulations, Routes, and Dosage Regimens 95
7 Mechanisms And End Points Of Drug Toxicity 131
8 Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF 143
9 Repeat-Dose Toxicity Studies 173
10 Genotoxicity 183
11 QSAR Tools For Drug Safety 223
12 Toxicogenomics 241
13 Immunotoxicology In Drug Development 247
14 Nonrodent Animal Studies 293
15 Developmental And Reproductive Toxicity Testing 331
16 Carcinogenicity Studies 363
17 Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment 395
18 Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment 403
19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation 425
20 Safety Pharmacology 457
21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products 477
22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs 507
23 Special Case Products: Imaging Agents 529
24 Special Case Products: Drugs For Treatment Of Cancer 535
25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology) 543
26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology 551
27 Occupational Toxicology In The Pharmaceutical Industry 571
28 Strategy and Phasing For Nonclinical Drug Safety EvaluationIn The Discovery and Development of Pharmaceuticals 585
29 The Application of In Vitro Techniques In Drug Safety Assessment 603
30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond 635
31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs) 683
32 Statistics In Pharmaceutical Safety Assessment 707
33 Combination Products: Drugs and Devices 767
34 Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals 777
35 Tissue, Cell, and Gene Therapy 789
36 Adverse Outcome Pathways in Drug Safety Assessment 801
Appendix A: Selected Regulatory and Toxicological Acronyms 805
Appendix B: Definition Of Terms And Lexicon of "Clinical" Observations in Nonclinical (Animal) Studies 807
Appendix C: Notable Regulatory Internet Addresses 811
Appendix D: Glossary Of Terms Used in The Clinical Evaluation of Therapeutic Agents 817
Appendix E: Common Vehicles For The Nonclinical Evaluation of Therapeutic Agents 821
Appendix F: Global Directory of Contract Toxicology Labs 919
INDEX 945
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
